MedPath
NMPA Approval

Donanemab Injection

国药准字SJ20240047

December 17, 2024

Drug Information

多奈单抗注射液

记能达

注射剂

20ml:350mg

生物制品

December 17, 2024

December 16, 2029

Company Information

Applicant Company

Lilly Corporate Center, Indianapolis, IN 46285, United States of America

Manufacturing Company

LILLY FRANCE

Z.A.-Centre de production, 2 rue du Colonel Lilly, Fegersheim 67640, FRANCE

© Copyright 2025. All Rights Reserved by MedPath
多奈单抗注射液 - NMPA 批准文号 | MedPath